Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,976,607
  • Shares Outstanding, K 113,036
  • Annual Sales, $ 0 K
  • Annual Income, $ -109,960 K
  • EBIT $ -275 M
  • EBITDA $ -292 M
  • 60-Month Beta 0.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.60

Options Overview Details

View History
  • Implied Volatility 77.44% (+2.27%)
  • Historical Volatility 47.70%
  • IV Percentile 25%
  • IV Rank 17.32%
  • IV High 170.22% on 08/12/25
  • IV Low 58.01% on 09/04/25
  • Expected Move (DTE 1) 0.95 (2.71%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 9,100
  • Volume Avg (30-Day) 13,930
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 246,336
  • Open Int (30-Day) 256,153
  • Expected Range 34.23 to 36.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.89
  • Number of Estimates 11
  • High Estimate -0.82
  • Low Estimate -1.01
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -178.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.81 +4.05%
on 12/03/25
39.99 -12.03%
on 12/04/25
-1.63 (-4.43%)
since 11/28/25
3-Month
26.17 +34.43%
on 10/01/25
43.15 -18.47%
on 11/12/25
+8.90 (+33.87%)
since 09/30/25
52-Week
18.92 +85.94%
on 04/09/25
43.55 -19.22%
on 01/06/25
-4.59 (-11.54%)
since 12/30/24

Most Recent Stories

More News
This Small But Mighty Stock Could Surprise Investors in 2026

This under-the-radar biotech stock is setting up for a big 2026.

VKTX : 35.18 (-0.40%)
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 35.18 (-0.40%)
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity

VKTX : 35.18 (-0.40%)
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome

VKTX : 35.18 (-0.40%)
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 35.18 (-0.40%)
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status

VKTX : 35.18 (-0.40%)
Viking Therapeutics: High Risk, High Reward Play

Viking Therapeutics stock surges as Phase 3 trials progress for its GLP-1 obesity drug, with analysts seeing major upside potential

VKTX : 35.18 (-0.40%)
NVO : 50.88 (-0.66%)
LLY : 1,074.68 (-0.47%)
PLTR : 177.75 (-1.71%)
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

VKTX : 35.18 (-0.40%)
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735

VKTX : 35.18 (-0.40%)
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time 

VKTX : 35.18 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 36.39
2nd Resistance Point 35.95
1st Resistance Point 35.56
Last Price 35.18
1st Support Level 34.73
2nd Support Level 34.29
3rd Support Level 33.90

See More

52-Week High 43.55
Last Price 35.18
Fibonacci 61.8% 34.14
Fibonacci 50% 31.24
Fibonacci 38.2% 28.33
52-Week Low 18.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar